NYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis $12.10 +0.18 (+1.47%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$12.10 -0.01 (-0.08%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Biohaven Stock (NYSE:BHVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biohaven alerts:Sign Up Key Stats Today's Range$11.75▼$12.2750-Day Range$11.93▼$17.1252-Week Range$7.48▼$18.57Volume1.37 million shsAverage Volume2.65 million shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/APrice Target$18.69Consensus RatingModerate Buy Company Overview Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and immunological disorders. The company uses proprietary drug-development platforms to pursue treatments for conditions with significant unmet medical needs, including migraine, epilepsy, obsessive-compulsive disorder and other central nervous system diseases. Biohaven’s pipeline has included small-molecule and biologic candidates such as troriluzole, an investigational therapy being studied in several neurological disorders, and other programs targeting ion channels, glutamate signaling and immune pathways. Its research programs span both clinical-stage and earlier-stage candidates, although the status and indications of individual programs may change as development progresses. The company was originally known as Biohaven Pharmaceutical Holding Company and developed the migraine medicines Nurtec ODT and Zavzpret. Pfizer acquired Biohaven’s commercial CGRP migraine portfolio in 2022, while the current Biohaven Ltd. retained and continued developing a separate pipeline of investigational medicines. Biohaven is headquartered in New Haven, Connecticut, and its operations and clinical-development activities serve patients and research markets internationally. Vlad Coric has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Biohaven Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreBHVN MarketRank™: Biohaven scored higher than 72% of companies evaluated by MarketBeat, and ranked 182nd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBiohaven has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on 2 strong buy ratings, 8 buy ratings, 5 hold ratings, and 2 sell ratings.Upside PotentialBiohaven has a consensus price target of $18.69, representing about 54.4% upside from its current price of $12.11.Amount of Analyst CoverageBiohaven has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biohaven's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($3.33) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 31.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biohaven's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.63% of the float of Biohaven has been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 6.43.Change versus previous monthShort interest in Biohaven has recently decreased by 6.82%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.38 News SentimentBiohaven has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Biohaven this week, compared to 4 articles on an average week.Search Interest6 people have searched for BHVN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Biohaven to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biohaven's insider trading history. Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BHVN Stock News HeadlinesStocktwits biotech dealmaker — Viatris and GE Healthcare buy what they can sell; Biohaven and Alector sell rightsOctober 9 at 12:34 AM | msn.comBiohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in AsiaOctober 8 at 7:29 PM | finance.yahoo.comNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafer-scale chip that does in minutes what current AI needs days to finish. Unlike conventional chips cut from silicon wafers, this technology uses the entire wafer as one giant chip, running on a fraction of the power. Gilder won't name the company publicly, but he's ready to hand it over.October 10 at 1:00 AM | Eagle Publishing (Ad)Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseaseOctober 8 at 4:00 AM | prnewswire.comBiohaven Ltd. (NYSE:BHVN) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsOctober 8 at 2:28 AM | americanbankingnews.comBiohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026September 28, 2026 | prnewswire.comHas Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?September 25, 2026 | finance.yahoo.comBiohaven's Kv7 Program Remains Key Stock Driver, UBS SaysSeptember 18, 2026 | marketscreener.comMSee More Headlines BHVN Stock Analysis - Frequently Asked Questions How have BHVN shares performed this year? Biohaven's stock was trading at $11.26 at the beginning of the year. Since then, BHVN stock has increased by 7.5% and is now trading at $12.1050. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) announced its quarterly earnings data on Monday, August, 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.15. When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings8/10/2026Today10/10/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BHVN's financial health is in the Green zone, according to TradeSmith. BHVN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CIK1935979 Webwww.biohaven.com Phone203-404-0410FaxN/AEmployees274Year Founded2014Price Target and Rating Average Price Target for Biohaven$18.69 High Price Target$42.00 Low Price Target$9.00 Potential Upside/Downside+54.4%Consensus RatingModerate Buy Rating Score (0-4)2.59 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$738.82 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,328.94% Return on Assets-138.27% Debt Debt-to-Equity Ratio21.23 Current Ratio4.73 Quick Ratio4.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book31.04Miscellaneous Outstanding Shares151,040,000Free Float130,200,000Market Cap$1.83 billion OptionableOptionable Beta1.35 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:BHVN) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | SponsoredElon’s Hiding a Potential $20 Trillion Monster Inside TeslaElon Musk says there is a product inside Tesla's factories he calls the biggest ever made, ten times bigger th...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
